Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of mogroside V (MV) in preparation of medicine with protection effect on neuronal injury caused by Parkinson's disease (PD)

A technology of neuron damage and mogroside, which is applied in drug delivery, drug combination, nervous system diseases, etc., can solve problems such as hyperacetylation and mitochondrial dysfunction, and achieve the effect of alleviating mitochondrial dysfunction

Pending Publication Date: 2022-02-15
AFFILIATED HOSPITAL OF GUILIN MEDICAL UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

SIRT3 knockout results in hyperacetylation and impaired mitochondrial function, whereas SIRT4 or SIRT5 knockout has no similar consequences

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of mogroside V (MV) in preparation of medicine with protection effect on neuronal injury caused by Parkinson's disease (PD)
  • Application of mogroside V (MV) in preparation of medicine with protection effect on neuronal injury caused by Parkinson's disease (PD)
  • Application of mogroside V (MV) in preparation of medicine with protection effect on neuronal injury caused by Parkinson's disease (PD)

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0033] 1. Application of mogroside V in the preparation of a drug that has a protective effect on Parkinson's disease neuron damage:

[0034] 2. Materials and methods

[0035] 2.1. Animals and handling

[0036] Two-month-old male C57BL / 6 mice were purchased from Hunan Slake Jingda Experimental Animal Co., Ltd., China. All experiments in this application were performed in accordance with the guidelines of the Experimental Animal Ethics Committee of Guilin Medical College, China (approval number 2019-0011).

[0037] Thirty mice with similar exercise ability were randomly divided into Con group, Rot group, MV2.5 group, MV5 group and MV10 group. Phosphate buffered saline (PBS, pH 7.4) was used to dissolve MVs. Based on MV pharmacokinetic parameters and excellent bioavailability, 2.5, 5, and 10 mg / kg were administered orally for six consecutive days; then, 0.25 mg / kg The dosage was directed to the Rot-directed microinjection in the right striatum, and all the mice were kept for...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of MV in preparation of a medicine with protection effect on neuronal injury caused by PD. The protection effect of the MV on neurotoxicity induced by Rotenone (Rot) is researched; in-vivo and in-vitro models of PD are established; then behavioristics and nerve injury, cell viability, ROS (reactive oxygen species) level, mitochondrial membrane potential (MMP), mitochondrial respiratory chain function, early apoptosis and ATP (adenosine triphosphate) level of model mice are detected; and finally, by up-regulating Sirtuin 3 (SIRT3), the action mechanism of the MV in the neuroprotection of PD is discussed.

Description

【Technical field】 [0001] The invention belongs to the technical field of drugs for treating Parkinson's disease, and relates to the application of mogroside V in the preparation of drugs with protective effect on neuron damage in Parkinson's disease. 【Background technique】 [0002] Parkinson's disease (PD) is one of the most common neurodegenerative movement disorders in humans, second only to Alzheimer's disease (AD). The characteristic pathological feature of PD is the progressive loss of dopaminergic neurons in the substantia nigra (SN) of the midbrain, resulting in a significant decrease in striatal dopamine (Dopamine, DA). Loss of DA leads to impairment of the nigrostriatal system and development of PD. The cause of PD is unknown. At the molecular level, mitochondrial dysfunction has been shown to be a key factor leading to the progressive loss of dopaminergic neurons in PD patients. Autopsy studies found mitochondrial complex I (complex I) activity and ubiquitin ket...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/704A61K36/42A61K9/48A61K9/08A61P25/16
CPCA61K31/704A61K36/42A61K9/0053A61K9/0019A61K9/48A61K9/08A61P25/16
Inventor 陈敏罗汉将
Owner AFFILIATED HOSPITAL OF GUILIN MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com